Core Insights - The 90th National Pharmaceutical Trade Fair (PHARMCHINA) successfully concluded, showcasing the transformation of China's pharmaceutical industry from generic drugs to innovation-driven development [2][3] - The event attracted over 20,000 professional attendees and featured 2,907 exhibiting companies, highlighting its significance as a comprehensive platform for policy interpretation, innovation display, trade cooperation, and academic exchange [2][3] Industry Overview - The event's theme "Quality Leads to New Chapters" emphasized the importance of quality in the pharmaceutical sector, reflecting the industry's evolution over the past 40 years [2] - The participation of 32% production and research institutions, 25% pharmaceutical distribution representatives, and 28% retail pharmacies and distributors indicates a diverse representation of the industry [2] Internationalization - The fair marked a significant step in internationalization, with 25 overseas brands from 15 countries and regions, including Germany, the USA, and Canada, showcasing advanced formulation technologies and innovative drug results [3][4] - The concurrent events attracted over 500 international guests, focusing on topics such as "Belt and Road" pharmaceutical cooperation and opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area [3] Innovation and Collaboration - The event featured over 300 new pharmaceutical health products launched in 2023, demonstrating a vibrant mix of industry giants and emerging biotech firms [4][5] - The establishment of a comprehensive ecosystem connecting policy, research, production, market, and capital was highlighted as a key value of the fair, facilitating collaboration among various stakeholders [3][4] Policy and Development Trends - Discussions at the event included the interpretation of the revised Drug Administration Law, emphasizing the importance of drug traceability and rare disease medication guarantees [5] - The focus on digital transformation, green supply chains, and cross-border circulation as strategic paths for the pharmaceutical distribution industry was underscored in the released development blueprints [5] Market Dynamics - The demand for health products is shifting from passive "disease treatment" to proactive "health management," indicating a broader trend in the pharmaceutical supply side [6] - The fair's conclusion signifies a new historical starting point for China's pharmaceutical industry, characterized by the collision of tradition and innovation, as well as local and global dialogues [6]

Group 1 - The company intends to acquire 64.81% of Imexpharm Corporation (IMP) in Vietnam for approximately 5.73 trillion VND, equivalent to about 1.587 billion RMB, which represents 10.92% of the company's latest audited net assets [2][3] - The acquisition will be executed by LIAN SGP, a wholly-owned subsidiary of the company's controlling subsidiary, Lijun Group, and will not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [2][3] - The transaction has been approved by the company's board of directors and does not require shareholder approval [2][3] Group 2 - The target company, IMP, is a leading pharmaceutical enterprise in Vietnam, primarily engaged in the research, production, and sale of pharmaceuticals, including antibiotics and cardiovascular drugs, which align well with the existing product portfolio of Lijun Group [5][6] - The acquisition is expected to strengthen the company's international market presence and support its long-term strategy for sustainable development in the pharmaceutical sector [8] Group 3 - The transaction is subject to certain conditions, including regulatory approvals in Vietnam, and the company will comply with all necessary legal and regulatory requirements [3][10] - The acquisition will not involve personnel placement, land leasing, or debt restructuring, and upon completion, IMP will become a controlled subsidiary within the company's consolidated financial statements [8][9]